Bangladesh's pharmaceutical manufacturers are hoping for a more stable supply of active pharmaceutical ingredients (APIs) and improved production efficiency under the proposed budget for fiscal year 2026-27, which expands duty-free access to a wide range of raw materials used in medicine production.